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Abstract
Objective—To examine the relationships between physical growth and medications prescribed for
symptoms of attention-deficit hyperactivity disorder in children with HIV.
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Methods—Analysis of data from children with perinatally acquired HIV (N = 2251; age 3–19
years), with and without prescriptions for stimulant and nonstimulant medications used to treat
attention-deficit hyperactivity disorder, in a long-term observational study. Height and weight
measurements were transformed to z scores and compared across medication groups. Changes in z
scores during a 2-year interval were compared using multiple linear regression models adjusting for
selected covariates.
Results—Participants with (n = 215) and without (n = 2036) prescriptions were shorter than
expected based on US age and gender norms (p < .001). Children without prescriptions weighed less
at baseline than children in the general population (p < .001) but gained height and weight at a faster
rate (p < .001). Children prescribed stimulants were similar to population norms in baseline weight;
their height and weight growth velocities were comparable with the general population and children
without prescriptions (for weight, p = .511 and .100, respectively). Children prescribed nonstimulants
had the lowest baseline height but were similar to population norms in baseline weight. Their height
and weight growth velocities were comparable with the general population but significantly slower
than children without prescriptions (p = .01 and .02, respectively).
Conclusion—The use of stimulants to treat symptoms of attention-deficit hyperactivity disorder
does not significantly exacerbate the potential for growth delay in children with HIV and may afford
opportunities for interventions that promote physical growth. Prospective studies are needed to
confirm these findings.
Index terms
HIV/AIDS; children and adolescents; height; weight; ADHD medication side effects
HIV infection has been reclassified as a chronic medical condition, leading to increased study
of the long-term mental health care needs of people with HIV. Children and adolescents with
HIV experience significant, multiple risks to mental health and quality of life, including viral
infection of the central nervous system, viral and drug exposure in utero, developmental delays,
poverty, inadequate support networks, unstable housing, and parental mental illness.1 These
factors place children and adolescents with HIV at risk for adverse behavioral outcomes,
including symptoms of attention-deficit hyperactivity disorder (ADHD).1 With an estimated
prevalence of 5 to 7% among school-aged children, ADHD is one of the most common pediatric
neurobehavioral disorders.2 The prevalence is higher in children who have comorbid
developmental conditions such as intellectual disability and autism spectrum disorders.3,4
Clinical concerns specific to the presence of comorbid HIV and untreated ADHD are that
inattentiveness might impair a child’s or adolescent’s ability to adhere to antiretroviral
treatment, whereas impulsivity might impair an adolescent’s ability to practice health-
promoting behaviors (e.g., safe sex).
Psychopharmacologic treatments for ADHD include stimulants and nonstimulants, both
commonly prescribed for children with HIV and ADHD. Stimulant efficacy in children and
adolescents is well established.2,5,6 For a variety of reasons, including stimulant failure or
intolerance, stigma, and potential for abuse, clinicians often prescribe nonstimulants to treat
ADHD. One of the most disputed adverse side effects of stimulant medication is growth
attenuation in children.2 Although some evidence suggests that age-related increases in height
and weight may be diminished in children treated with stimulants,7,8 the clinical relevance of
the growth delay remains controversial.9,10 Clinical trials have not demonstrated significant
growth attenuation in children treated with nonstimulants.11,12
Children and adolescents with HIV are at risk for growth failure as a complication of their
disease.13,14 For children with comorbid HIV and ADHD, the use of stimulants to treat ADHD
may exacerbate the risk of growth failure related to HIV. There has been little empirical
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investigation into growth rates in children with HIV taking stimulants or nonstimulants for
ADHD. The primary objective of this study was to examine the relationship between physical
growth, as measured by height and weight, in children and adolescents with HIV and the use
of commonly prescribed medications for treatment of ADHD. We hypothesized that children
with prescriptions for stimulants would be smaller for age and would gain height and weight
more slowly than their peers with HIV who were not prescribed stimulant medications.
METHODS
This study evaluated data from the Pediatric AIDS Clinical Trials Group 219C cohort study
(P219C), a multicenter, longitudinal observational study of HIV-infected and uninfected,
perinatally exposed children and adolescents conducted from September 2000 until May 2007.
P219C was a revision of Pediatric AIDS Clinical Trials Group protocol 219 initiated in 1993
to study long-term effects of in utero exposure to antiretroviral medications and complications
of HIV infection. P219C was approved by local institutional review boards at more than 80
participating sites in the United States and Puerto Rico. Informed consent and assent were
obtained according to local institutional guidelines. On enrollment, study nurses abstracted
participants’ medical records to obtain medical and treatment histories, including diagnoses
and antiretroviral and concomitant medications. Follow-up visits included physical
examinations (including Tanner staging for children aged 8 years and older), laboratory studies,
and self-reports from children and parents or caregivers to provide updated demographic
information, medical history (including psychiatric and neurologic diagnoses), and quality of
life information.
Participants
This study included children and adolescents enrolled in P219C with perinatally acquired HIV
infection, with and without prescriptions for one or more of the stimulant or nonstimulant
medications commonly prescribed to treat symptoms of attention-deficit hyperactivity disorder
(ADHD) (Table 1). Among children prescribed at least one of the medications, we included
those who started their first medication between the ages of 3 and 19 years, continued that
medication for at least 1 month, and had at least 2 growth measurements (height or weight)
within 2 years after the start of their first medication. For participants who never received any
of the medications, we included children between the ages of 3 and 19 years who had at least
2 growth measurements (height or weight) within 2 years after enrollment into P219C or after
the age of 3 years for those who enrolled before the age of 3 years. We considered the perinatally
exposed but uninfected cohort in P219C (n = 1778), but too few (n = 31) had prescriptions for
any of the selected medications to make meaningful comparisons; thus, this group was not
considered further.
Measures of Physical Growth
Height and weight measurements were obtained every 3 months (±1 month) from evaluations
performed in routine clinical care or during scheduled study visits, according to the
standardized protocol in P219C. Children had standing heights measured to the nearest 0.1 cm
using a stadiometer; weights were taken without shoes. One height and weight measurements
were recorded at each visit. For participants with prescriptions for at least one of the
medications in Table 1, baseline height and weight measurements were defined as the earliest
measurements available after the start of medication. For participants with no history of
treatment with the selected medications, baseline height and weight measurements were
defined as the first measurements taken either at enrollment or after enrollment into P219C or
the first measurements taken after the age of 3 years for those younger than 3 years at
enrollment. The second height and weight measurements were defined as the latest
measurements available within 2 years of baseline. Study nurses recorded medication dates as
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reported by parents or older participants or as documented in the medical records available to
the study.
Baseline Tanner stage, for children aged 8 years and older, was obtained from the latest record
available in P219C, either before or at the time of the baseline height or weight measurement.
Tanner staging was classified into 2 categories, Stage 1 and Stage 2 or higher, to capture the
onset of puberty (and expected growth spurt) and to minimize the potential for misclassification
errors across Stages 2 and higher. Children were classified as Tanner Stage 1 if they were
younger than 8 years at baseline or if they were older than 8 years, with no Tanner assessment
before or at baseline, but with an assessment subsequent to baseline indicating Tanner Stage
1. Children who did not meet these criteria were recorded as having missing Tanner stage data.
Statistical Analysis
Height-for-age and weight-for-age z scores were calculated with reference to national norms
for US children and adolescents15 using the earliest and latest height and weight measurements
within the 2-year interval. This metric was used to control for age-related differences in
developmental trajectories of height and weight gains. Baseline height and weight z scores
were compared across groups defined by medication class (stimulant versus none; nonstimulant
vs. none) using pairwise t tests and compared with population norms within each subgroup
using a one-sample t test of mean z score equal to 0. Changes in z scores were calculated by
subtracting the z score obtained at baseline from the latest z score within the 2-year interval
after baseline, divided by the time between measurements (in years). Changes in z scores were
compared between participants with and without prescriptions using multiple linear regression
models that adjusted for selected covariates. Separate univariate linear regression models for
the change in z scores on each of the potential covariates were fit as well as a full multiple
linear regression model that included medication class and all covariates. Forward and
backward selection approaches were used to select the final model, with medication class
forced into the model.
Covariates
Baseline characteristics of participants and primary caregivers were selected as potential
covariates of physical growth. For participants, these characteristics included age, sex, race or
ethnicity, Tanner stage, antiretroviral medication class (and switching antiretroviral regimens
during the 2-year observation period), diagnoses of neurologic or psychiatric disorders,
stressful life events, serious academic difficulties (repeated a grade or receiving special
educational services), and limitations on school attendance or daily activities because of illness.
Indicators of the child’s disease status (CD4 count and percent, HIV RNA, and Centers for
Disease Control and Prevention Class C classification) were collected closest to and within 6
months of baseline and considered as potential covariates. For parents and caregivers, the
potential covariates included educational level and familial relationship to the child (biological
parent, other relative, and foster/adoptive parent).
Covariates with p < .25 in either the univariate models or the full multiple linear regression
models were initially considered as candidates in model selection. Each neurologic and
psychiatric diagnosis was considered, one at a time, after selection of a multivariate model to
evaluate any potential effect on medication class estimates. Variables retained in the final
model were considered significant when p < .05 and marginally significant when p < .10.16
All analyses used data submitted to the P219C data management center by May 2007 and were
conducted using SAS 9.1 software (SAS Institute, Cary, NC).
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RESULTS
Participants
Of the 2589 children with perinatal HIV infection enrolled in P219C, 367 had a prescription
for one or more of the medications shown in Table 1 and met inclusion criteria for this study.
Of these, 204 (56%) entered P219C with one or more prescriptions for the selected medications:
4 received their first prescription within 1 month before study entry, 16 within 1 to 3 months,
11 within 3 to 6 months, and 173 more than 6 months before study entry. As an adjunctive
measure, we had planned to examine premedication and post-medication growth rates in the
sample but were unable to do so because of the large proportion (200 of 367; 55%) of children
with prescriptions who entered P219C with medication history greater than 1 month.
Of the 367 who met inclusion criteria, 265 had at least 2 height measurements and 268 had at
least 2 weight measurements within 2 years of starting their first medication. At some point
during the 2-year interval, 50 children either switched from one medication class to the other
or held prescriptions for medications in both classes. Because it would not be possible to
determine the relative effect of each regimen on the child’s height and weight trajectories, these
50 were excluded from the analyses, resulting in 215 participants with 2 height measurements
and 218 with 2 weight measurements collected within 2 years after starting their first
medication. Of the 2180 participants in P219C who did not have prescriptions for the selected
medications, 2036 had at least 2 height measurements within 2 years after enrollment and 2047
had at least 2 weight measurements.
Table 2 presents the distribution of demographic characteristics of participants included in the
height analysis; the distribution was almost identical for those included in the weight analysis.
The significant difference in age distribution between participants with prescriptions and those
without (p < .001) was due to the smaller percentage among those with prescriptions who were
3 to 6 years (3%) and the larger percentage who were 9 to 12 years (42%). The percentage of
boys among those with prescriptions was significantly higher than among those without (64
vs. 46%, p < .001). Among children with prescriptions, 51% lived with their biological parents
or other relatives; among those without prescriptions, 75% lived with biological relatives (p
< .001). There was no significant difference in racial or ethnic distribution or baseline Tanner
stage between participants with and without prescriptions. Of the 2251 children included in
this study, 99 (4.4%) had no recorded Tanner assessment available; their data were excluded
from subsequent analyses using Tanner staging.
Timing of Measurements
The baseline measurements were defined as the first measurements in P219C obtained after
the medication start date; however, the majority of eligible study participants with prescriptions
for either a stimulant or non-stimulant entered P219C having held the prescription for at least
1 month. At baseline, the median interval between medication start date and the first available
height and weight measurements was 2.0 months (interquartile range = 0.9–5.7 months). The
median interval between the first and second assessments, used to assess height growth rates,
was 21.6 months (interquartile range = 19.3–23.2 months) for those with prescriptions and 17.5
months (interquartile range = 9.0–20.8 months) for those without prescriptions; these
distributions were similar for weight.
Medication Class and Neurologic or Psychiatric Diagnoses
Stimulants were the first medicines prescribed for the majority (83%) of participants with
prescriptions (Table 1), and the majority (63%) of these children had one or more reported
neurologic or psychiatric diagnoses (Table 3). Except for 2 diagnostic categories (hypotonia/
hypertonia and microcephaly/failure to thrive), the prevalence of reported diagnoses was
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significantly higher for children with prescriptions than for those without (Fisher’s exact test,
Table 3). The observed percentages in Table 3 might suggest that the nonstimulant class was
driving the results of the comparisons between those on medications versus those not on
medications; however, additional exploration using Pearson’s χ2 test and logistic regression
analyses comparing the children in each medication class to the group without medications
revealed that both medication classes were contributing to the significant differences observed
across all diagnostic categories except encephalopathy/cerebral palsy (results available on
request). It is important to note that there were relatively high numbers of children in each
medication class with no recorded diagnosis: 40% of children with prescriptions for stimulants
and 19% of those with prescriptions for nonstimulants (Table 3). For this reason, our findings
with respect to medication class and diagnostic category should be interpreted with caution.
Medication Class and Changes in Height
Baseline Height z Scores—Participants with and without prescriptions were shorter on
average than the general population of US children of the same age and sex (p < .001; Table
4). Children with prescriptions for nonstimulants had the lowest mean height z score at baseline
and were significantly shorter than those who did not have prescriptions for either medication
class (p = .008). Children without prescriptions were marginally shorter than children with
prescriptions for stimulants (p = .06).
Height Growth Rate—The mean change in height z score was significantly different from
0 for children without prescriptions (mean change = 0.03 standard deviation (SD) per year, p
< .001; Table 4), indicating they were gaining height at a faster rate than children of the same
age and sex in the general population. The mean change in height z score was marginally
different from 0 for children with prescriptions for nonstimulants (mean change = −0.14 SD
per year, p = .06), indicating they were growing more slowly than their peers in the general
population. Children with prescriptions for stimulants grew at a rate comparable with their
peers in the general population (mean change = 0.01 SD per year, p = .75).
After adjusting for all potential covariates, the final multiple linear regression model for change
in height z scores (Table 5) showed medication class was a significant predictor of height
growth (p = .02). Children with prescriptions for nonstimulants had a smaller mean change in
height z score than children without prescriptions (slope = −0.159, 95% confidence interval:
−0.271 to −0.048, p = .005). In contrast, children with prescriptions for stimulants were similar
in height growth rate to children without prescriptions (slope = −0.007, p = .80). Thus, children
with HIV who were prescribed stimulant medications were found to have similar growth in
height to children with HIV who were not prescribed any of the medications used to treat
attention-deficit hyperactivity disorder (ADHD). Children with HIV who had prescriptions for
nonstimulants were found to have made fewer gains in height than either their peers with
prescriptions for stimulants or those with no prescriptions for ADHD medications. The final
model also showed that the mean change in height z scores was significantly smaller (slower
growth rate) for children with higher viral load (slope = −0.028, p = .001) and lower baseline
height (slope = −0.059, p < .001). It was significantly larger (faster growth rate) for girls (slope
= 0.030, p = .04), adolescents aged 15 to 18 years (slope = 0.077, p = .04), and children with
illness-related limitations in daily activities (slope = 0.050, p = .03). In univariate analyses,
baseline Tanner stage had a marginally significant association with change in height z scores
(slope = −0.030, p = .054); however, it was not significant when included in the multiple linear
regression analyses and thus excluded from the final model for height growth rate.
Medication Class and Changes in Weight
Baseline Weight z Scores—Children who did not have prescriptions were significantly
below average in weight compared with their peers in the general population (mean weight z
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score = −0.11, p < .001; Table 4). There were no significant differences in mean weights at
baseline between the children with prescriptions for stimulants or nonstimulants compared
with children in the general population (p = .66 and .16, respectively) and to those without
prescriptions (p = .45 and .30, respectively).
Weight Growth Rate—The mean change in weight z score was significantly different from
0 for children without prescriptions (mean change = 0.03 SD per year, p < .001; Table 4),
indicating they were gaining weight at a faster rate than children in the general population. The
mean change in weight z score was marginally significant for children with prescriptions for
nonstimulants (mean change = −0.17 SD per year, p = .07), indicating they were gaining weight
more slowly than their peers. Children with prescriptions for stimulants grew at a rate
comparable with their peers in the general population (mean change = −0.02, p = .51).
After adjusting for all potential covariates, the final multiple linear regression model for change
in weight z scores (Table 6) showed medication class was a significant predictor of weight gain
(p = .02). Children prescribed nonstimulants had a significantly smaller mean change in weight
z score than children who did not have prescriptions for either medication class (slope = −0.182,
95% confidence interval: −0.329 to −0.036, p = .02). The mean change in weight z score for
children prescribed stimulants was marginally smaller than the mean change for children
without prescriptions (slope = −0.052, 95% confidence interval: −0.115 to 0.010, p = .10).
These findings suggest that the stimulant medications had a subtle, though not statistically
significant, adverse influence on weight gain in children with HIV who had prescriptions for
medicines used to treat ADHD, relative to children with HIV who were not prescribed any of
these medicines. In contrast, nonstimulants were associated with significantly smaller weight
gains in children with HIV who were prescribed this form of medication for ADHD, relative
to children with HIV who were not prescribed medications for ADHD. The final model also
showed the mean change in weight z score was significantly smaller for children with higher
viral load (slope = −0.052, p < .001), lower baseline weight (slope = −0.042, p < .001), those
aged older than 12 to 15 years (slope = −0.091, p = .02), and those aged older than 15 to 18
years (slope = −0.193, p < .001). In univariate analyses, baseline Tanner stage was not
significantly associated with change in weight z scores (slope = 0.017, p = .36); however, it
was significant in the multiple linear regression analyses and thus included as a correlate in
the final model. Participants at Tanner Stage 2 and higher demonstrated significantly greater
weight gain (slope = 0.122, p < .001) than those at Tanner Stage 1.
DISCUSSION
The children and adolescents in this study were shorter on average than their peers in the general
population, whether or not they held prescriptions for stimulant or nonstimulant medications,
and the children who did not have prescriptions for either medication class were significantly
below average in weight compared with population norms. These findings are consistent with
previous studies of physical growth in children and adolescents with HIV.13,14 Children with
prescriptions for either stimulants or nonstimulants were similar in weight to their peers in the
general population; these finding are not consistent with previous research showing
significantly lower weight in children with HIV.13,14 For children with HIV who were
prescribed stimulants, we found no significant difference in height growth rate and a marginally
significant difference in weight growth relative to children with HIV who were not prescribed
medications used to treat attention-deficit hyperactivity disorder (ADHD). Interestingly, in
contrast, children prescribed nonstimulants were found to have significantly slower rates of
growth in both height and weight relative to children with HIV who were not prescribed any
medications for ADHD. Thus, our findings indicate that stimulants exert a subtle, adverse
influence on weight gain, whereas nonstimulants are associated with significantly increased
risks for growth delays in both height and weight, beyond that attributable to HIV alone. It
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should be noted that with the sample sizes used, the minimal stimulant effect size that the
analysis could detect using 5% significance level and with 80% power is 0.10. Hence, a
marginally significant result may signal the plausible presence of a smaller effect not detectable
with the sample size used but which may be clinically interesting.
The interval between height and weight measurements was shorter for children with
prescriptions than for those without, reflecting the need for frequent monitoring of children
with prescriptions for medicines used to treat ADHD. For the children prescribed stimulants,
it is possible that these more frequent clinic visits provided additional opportunities for
clinicians to initiate interventions that directly or indirectly improved the children’s physical
growth. Alternatively, the children’s prescribing physicians may have been inclined to
prescribe the stimulants to those youth with HIV who were not significantly undernourished
at their premedication baseline, but limitations in the pretreatment growth data precluded us
from examining this possibility.
Children prescribed nonstimulants had the lowest mean height z score at the time of the first
measurement and were significantly shorter than those without prescriptions. Their height
growth rate was marginally slower than expected based on population norms and significantly
slower (after adjusting for important covariates) than children with no prescriptions. They
gained weight more slowly (marginally) than peers in the general population and showed
significantly smaller weight gain than children in this study who did not have prescriptions.
This group also had the largest diversity of neurologic and psychiatric diagnoses, including
cerebral palsy, anxiety and affective disorders, and failure to thrive. This pattern, combined
with the diversity of pharmacodynamic properties and side-effect profiles of the 5
nonstimulants in this study, precludes attribution of the study findings to any particular
pharmacological mechanism.
Almost one half of the children with prescriptions for stimulants and more than one third of
those prescribed nonstimulants had a reported diagnosis of ADHD or other behavior disorder,
but there were no reported psychiatric diagnoses for a relatively large proportion of the sample:
40% of children with prescriptions for stimulants and 19% with prescriptions for
nonstimulants. The availability of data concerning neurologic and psychiatric diagnoses varied
across sites in P219C because of differences in the sites’ access to medical and psychiatric
records, and the results reported here probably underestimate the true frequency of psychiatric
diagnoses in the P219C cohort. Similarly, the fact that ADHD and behavior problems were
only reported for 38% of children on nonstimulants suggests that these medications were
prescribed for other reasons, for example, for depression or anxiety disorders. Nevertheless,
given the present study’s focus on ADHD medication side effects on physical growth, the
availability of data central to the analyses was not affected by this limitation.
The study was limited by lack of control over the interval between medication start date and
the first height and weight measurements. The median interval of 2 months was longer than
anticipated because of the large proportion of children who entered P219C with prescriptions
for stimulants or nonstimulants. Although we do not believe this longer interval at baseline
significantly affected our ability to capture changes in height growth rate during the 2-year
period, it is possible that it affected capture of the earliest effects of stimulant medication on
appetite and weight gain. The study was also limited by lack of data concerning the children’s
adherence to stimulants and nonstimulants and concomitant use of antipsychotic medications.
An increase in weight as a side effect of antipsychotic medications17 could offset a decrease
in weight as a side effect of stimulant medications. Knowledge of the children’s access to
nutritionists and use of dietary supplements would have assisted in the interpretation of results
but was unavailable. Finally, a longer period of follow-up, in conjunction with information
about the children’s adherence to stimulant and nonstimulant medications, would have allowed
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a more detailed examination of changes in physical growth as a function of medication use and
advancing HIV disease.
The findings of this study indicate that the use of stimulant medications to treat symptoms of
ADHD in children and adolescents with HIV does not significantly exacerbate the potential
for growth delay beyond the risk attributable to HIV alone. Nevertheless, given the importance
of weight maintenance in children with HIV disease, the subtle effects observed in this sample
warrant clinical consideration and indicate the need for additional research to replicate the
findings. Furthermore, the results suggest that children and adolescents with HIV who receive
treatment for problem behaviors might experience unexpected benefits in physical growth,
possibly because of increased contact with clinical personnel or because the children and/or
their caregivers become more reliable and responsible for their health care regimen and general
well-being. Future research should include prospective studies designed to evaluate the effect
of medical treatment for ADHD on the physical growth of children and adolescents with HIV
and examine the cost of the side effects relative to the benefits of treatment.
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Table 1
Medications Selected for Study and Medication History of Study Participants (N = 367)
Generic Name First Prescribed, n (%) Ever Prescribed, n (%)
Stimulants
 Methylphenidate 211 (57) 321 (87)
 Mixed amphetamine salts (dextroamphetamine
saccharate, amphetamine aspartate, dextroamphetamine
sulfate, amphetamine sulfate)
72 (20) 125 (34)
 Dextroamphetamine sulfate 16 (4) 27 (7)
 Dexmethylphenidate 3 (1) 7 (2)
 Magnesium pemoline 1 (<1) 1 (<1)
Nonstimulants
 Clonidine Hcl 31 (8) 69 (19)
 Atomoxetine Hcl 8 (2) 43 (12)
 Bupropion Hcl 11 (3) 27 (7)
 Guanfacine Hcl 6 (2) 21 (6)
 Imipramine Hcl, desipramine Hcl 8 (2) 14 (4)
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Table 2
Selected Characteristics of Participants at the Time of Baseline Height Measurement
Characteristic Overall (N = 2251) With Prescriptions
(N = 215)
Without
Prescriptions (N =
2036)
p
Age at height measurement (yrs) <.001a
 3–6 470 (21%) 7 (3%) 463 (23%)
 >6–9 548 (24%) 66 (31%) 482 (24%)
 >9–12 636 (28%) 91 (42%) 545 (27%)
 >12–15 406 (18%) 36 (17%) 370 (18%)
 >15–18 191 (8%) 15 (7%) 176 (9%)
Female gender 1182 (53%) 78 (36%) 1104 (54%) <.001b
Race/ethnicity 0.141a
 White, non-Hispanic 289 (13%) 31 (14%) 258 (13%)
 Black, non-Hispanic 1332 (59%) 130 (60%) 1202 (59%)
 Hispanic 591 (26%) 47 (22%) 544 (27%)
 Others 39 (2%) 7 (3%) 32 (2%)
Primary caregiver <.001a
 Biological parent 1057 (47%) 54 (25%) 1003 (49%)
 Relative 584 (26%) 55 (26%) 529 (26%)
 Other adults 582 (26%) 95 (44%) 487 (24%)
 Other/unknown 28 (1%) 11 (5%) 17 (1%)
Tanner stage .793a
 Stage 1 1424 (66%) 140 (67%) 1284 (66%)
 Stage 2 or higher 728 (34%) 69 (33%) 659 (34%)
 Missing 99 (—) 6 (—) 93 (—)
HIV RNAc [in log(copies/mL)] .568d
 Mean (SD) 3.38 (0.91) 3.34 (0.88) 3.38 (0.91)
 Median 2.98 2.89 2.99
CD4 counte .036d
 Mean (SD) 857.6 (535.6) 784.5 (436.9) 865.4 (544.5)
 Median 778.0 738.0 781.0
CD4 percente .099d
 Mean (SD) 29.5 (10.9) 30.7 (11.1) 29.4 (10.8)
 Median 30.0 32.0 30.0
a
Pearson’s χ2 test, missing values excluded.
b
Fisher’s exact test.
c
Ten patients had no viral load (HIV RNA) data within 6 months from the date of height measurement (7 without prescriptions, 3 with prescriptions).
d
Student’s t test for 2 independent samples.
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e
Twenty-six patients had no CD4 count and CD4 percent data within 6 months from the date of height measurement (24 without prescriptions, 2 with
prescriptions). The distribution of characteristics was similar at the time of the baseline weight measurement.
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Table 3
First Medication Prescribed, by Selected Neurologic and Psychiatric Diagnoses, for Participants With Height
Growth Measurements (N = 2251)
Diagnostic Categorya First Medication Prescribed
Stimulant, n (%
of 183)
Nonstimulant, n (%
of 32)
None, n (% of
2036)
ADHD/behavior disorder*** 85 (46) 12 (38) 69 (3)
Encephalopathy/cerebral palsy* 21 (11) 13 (41) 206 (10)
Hypotonia/hypertonia 19 (10) 6 (19) 243 (12)
Intellectual disabilities/developmental disorder** 19 (10) 5 (16) 105 (5)
Epilepsy/seizure/infantile spasm** 13 (7) 4 (13) 64 (3)
Depression/anxiety/bipolar disorderb*** 9 (5) 6 (19) 47 (2)
Microcephaly/failure to thrive 9 (5) 4 (13) 99 (5)
At least one of the above*** 109 (60) 26 (81) 542 (27)
None of the above 74 (40) 6 (19) 1494 (73)
ADHD, attention-deficit hyperactivity disorder.
a
Includes diagnoses recorded until the time of the second height measurement.
b
Includes dysthymia and suicidal tendencies.
*
p < .05;
**
p < 0.01;
***
p < 0.001.
The distribution of diagnoses was similar for the group of participants with weight growth measurements. p values based on Fisher’s exact test of the
difference between the group with prescriptions (stimulants or nonstimulants) vs. the group without prescriptions. Both medication classes contributed
to the significant differences across all categories except encephalopathy/cerebral palsy.
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Table 5
Final Multiple Linear Regression Model of Change in Height z Scores Among Participants With and Without
Prescriptions for Selected Medications (n = 215)
Predictor Slope 95% Confidence Interval p
Intercept −0.040 −0.179 0.100 .571
Medication class — — — .020
 None 0.000 — — Ref
 Stimulant −0.007 −0.056 0.043 .796
 Nonstimulant −0.159 −0.271 −0.048 .005
Age group (yrs) — — — .005
 3–6 0.000 — — Ref
 >6–9 0.061 −0.001 0.123 .056
 >9–12 0.004 −0.058 0.066 .904
 >12–15 0.024 −0.041 0.089 .468
 >15–18 0.077 0.002 0.151 .044
Female 0.030 0.002 0.058 .039
Log(RNA) −0.028 −0.044 −0.012 .001
Baseline height z score −0.059 −0.072 −0.047 <.001
Interval between measurements −0.0002 −0.0003 −0.0001 .001
Limited school attendance 0.040 −0.005 0.085 .083
Limited activities 0.050 0.005 0.096 .029
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Table 6
Final Multiple Linear Regression Model of Change in Weight z Scores Among Participants With and Without
Prescriptions for Selected Medications (n = 218)
Predictor Slope 95% Confidence Interval p
Intercept 0.107 0.011 0.202 .029
Medication class — — — .016
 None 0.000 — — Ref
 Stimulant −0.052 −0.115 0.010 .100
 Nonstimulant −0.182 −0.329 −0.036 .015
Age group (yrs) — — — <.001
 3–6 0.000 — — Ref
 >6–9 0.011 −0.039 0.062 .655
 >9–12 −0.070 −0.124 −0.016 .011
 >12–15 −0.091 −0.168 −0.014 .021
 >15–18 −0.193 −0.286 −0.100 <.001
Tanner stage 2 and higher 0.122 0.054 0.171 <.001
Log(RNA) −0.052 −0.071 −0.033 <.001
Baseline weight z score −0.042 −0.056 −0.027 <.001
Encephalopathy/cerebral palsy −0.052 −0.107 0.004 .068
Microcephaly/failure to thrive −0.070 −0.148 0.009 .081
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